SK172197A3 - Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same - Google Patents
Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same Download PDFInfo
- Publication number
- SK172197A3 SK172197A3 SK1721-97A SK172197A SK172197A3 SK 172197 A3 SK172197 A3 SK 172197A3 SK 172197 A SK172197 A SK 172197A SK 172197 A3 SK172197 A3 SK 172197A3
- Authority
- SK
- Slovakia
- Prior art keywords
- compound
- formula
- angiotensin
- dyspeptic symptoms
- pharmaceutical composition
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 7
- 201000006549 dyspepsia Diseases 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000036454 renin-angiotensin system Effects 0.000 description 6
- 239000002083 C09CA01 - Losartan Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229960004773 losartan Drugs 0.000 description 5
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229960004349 candesartan cilexetil Drugs 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 0 *C1CCCCC1 Chemical compound *C1CCCCC1 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000001838 Angiotensin II receptor type 1 Human genes 0.000 description 1
- 108050009086 Angiotensin II receptor type 1 Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000010913 Type 1 Angiotensin Receptor Human genes 0.000 description 1
- 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9502219A SE9502219D0 (sv) | 1995-06-19 | 1995-06-19 | Novel medical use |
PCT/SE1996/000758 WO1997000070A1 (en) | 1995-06-19 | 1996-06-10 | Novel medical use |
Publications (1)
Publication Number | Publication Date |
---|---|
SK172197A3 true SK172197A3 (en) | 1998-07-08 |
Family
ID=20398663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1721-97A SK172197A3 (en) | 1995-06-19 | 1996-06-10 | Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same |
Country Status (28)
Country | Link |
---|---|
US (1) | US6096772A (xx) |
EP (1) | EP0840607B1 (xx) |
JP (1) | JPH11507921A (xx) |
KR (1) | KR19990023021A (xx) |
CN (1) | CN1091595C (xx) |
AT (1) | ATE214925T1 (xx) |
AU (1) | AU706660B2 (xx) |
BR (1) | BR9608472A (xx) |
CA (1) | CA2225175A1 (xx) |
CZ (1) | CZ289400B6 (xx) |
DE (1) | DE69620186T2 (xx) |
DK (1) | DK0840607T3 (xx) |
EE (1) | EE03385B1 (xx) |
ES (1) | ES2173294T3 (xx) |
HK (1) | HK1010152A1 (xx) |
HU (1) | HUP9901448A3 (xx) |
IL (1) | IL122659A (xx) |
IS (1) | IS4619A (xx) |
MY (1) | MY114716A (xx) |
NO (1) | NO975922D0 (xx) |
NZ (1) | NZ310606A (xx) |
PT (1) | PT840607E (xx) |
RU (1) | RU2209064C2 (xx) |
SE (1) | SE9502219D0 (xx) |
SK (1) | SK172197A3 (xx) |
UA (1) | UA55387C2 (xx) |
WO (1) | WO1997000070A1 (xx) |
ZA (1) | ZA964690B (xx) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
SE9800550D0 (sv) * | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
BR0102252B1 (pt) * | 2001-04-10 | 2013-10-22 | Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso | |
WO2003035039A1 (en) * | 2001-10-25 | 2003-05-01 | Depomed, Inc. | Methods of treatment using a gastric retained losartan dosage |
US7271269B2 (en) * | 2003-01-30 | 2007-09-18 | Lek Pharmaceuticals D.D. | Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods |
DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
US8979838B2 (en) | 2010-05-24 | 2015-03-17 | Arthrocare Corporation | Symmetric switching electrode method and related system |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
CA1334092C (en) * | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5250558A (en) * | 1992-01-28 | 1993-10-05 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis |
GB2263635A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
GB2263639A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
GB2263637A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted imidazo-fused 6-membered carbocycle or heterocycle as neurotensin antagonists |
GB2263638A (en) * | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrazoles, isoxazoles and isothiazoles as neurotensin antagonists |
DE4203872A1 (de) * | 1992-02-11 | 1993-08-12 | Thomae Gmbh Dr K | Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5212195A (en) * | 1992-05-13 | 1993-05-18 | Syntex (U.S.A.) Inc. | Substituted indole antagonists derivatives which are angiotensin II |
US5538991A (en) * | 1994-09-14 | 1996-07-23 | Merck & Co., Inc. | Endothelin antagonists bearing 5-membered heterocyclic amides |
-
1995
- 1995-06-19 SE SE9502219A patent/SE9502219D0/xx unknown
-
1996
- 1996-06-05 ZA ZA964690A patent/ZA964690B/xx unknown
- 1996-06-10 RU RU98101105/14A patent/RU2209064C2/ru not_active IP Right Cessation
- 1996-06-10 AT AT96918965T patent/ATE214925T1/de not_active IP Right Cessation
- 1996-06-10 EE EE9700366A patent/EE03385B1/xx not_active IP Right Cessation
- 1996-06-10 IL IL12265996A patent/IL122659A/xx not_active IP Right Cessation
- 1996-06-10 PT PT96918965T patent/PT840607E/pt unknown
- 1996-06-10 KR KR1019970709491A patent/KR19990023021A/ko not_active Application Discontinuation
- 1996-06-10 JP JP9502982A patent/JPH11507921A/ja active Pending
- 1996-06-10 DK DK96918965T patent/DK0840607T3/da active
- 1996-06-10 CZ CZ19973730A patent/CZ289400B6/cs not_active IP Right Cessation
- 1996-06-10 DE DE69620186T patent/DE69620186T2/de not_active Expired - Fee Related
- 1996-06-10 CA CA002225175A patent/CA2225175A1/en not_active Abandoned
- 1996-06-10 SK SK1721-97A patent/SK172197A3/sk unknown
- 1996-06-10 US US08/702,522 patent/US6096772A/en not_active Expired - Fee Related
- 1996-06-10 HU HU9901448A patent/HUP9901448A3/hu unknown
- 1996-06-10 ES ES96918965T patent/ES2173294T3/es not_active Expired - Lifetime
- 1996-06-10 AU AU11840/97A patent/AU706660B2/en not_active Ceased
- 1996-06-10 WO PCT/SE1996/000758 patent/WO1997000070A1/en not_active Application Discontinuation
- 1996-06-10 BR BR9608472A patent/BR9608472A/pt not_active Application Discontinuation
- 1996-06-10 NZ NZ310606A patent/NZ310606A/en unknown
- 1996-06-10 EP EP96918965A patent/EP0840607B1/en not_active Expired - Lifetime
- 1996-06-10 CN CN96196137A patent/CN1091595C/zh not_active Expired - Fee Related
- 1996-06-19 MY MYPI96002480A patent/MY114716A/en unknown
- 1996-10-06 UA UA97126085A patent/UA55387C2/uk unknown
-
1997
- 1997-11-25 IS IS4619A patent/IS4619A/is unknown
- 1997-12-16 NO NO975922A patent/NO975922D0/no not_active Application Discontinuation
-
1998
- 1998-10-14 HK HK98111234A patent/HK1010152A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69713890T2 (de) | Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht | |
RU2345790C2 (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
JP2002504516A (ja) | アンギオテンシンii型2リセプタ作用薬を含む医薬製剤およびその使用 | |
US5916904A (en) | Antimicrobial agent | |
SK172197A3 (en) | Using angiotensin ii type 1 receptor antagonists having an effect to dyspeptic symptoms and a pharmaceutical composition containing the same | |
SK87998A3 (en) | Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms | |
US6767905B2 (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction | |
CA2457982C (en) | Use of nefiracetam for treating neurodegeneration | |
NO975221L (no) | Ny farmakologisk anvendelse av AII-reseptorantagonister | |
KR101153571B1 (ko) | 테나토프라졸 및 히스타민 h2-수용체 길항제를 배합한제약 조성물 | |
JP2003535897A (ja) | アンギオテンシンiiアンタゴニストの新規使用法 | |
MXPA97010002A (es) | Nuevo uso medico | |
DE3915236A1 (de) | Pharmazeutische zubereitung | |
CN1140996A (zh) | 雷尼替丁和碳酸钙药物复合品 |